Literature DB >> 22876163

Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.

J Wang1, S S Xing, S B Guo, W Jin, W Zhang.   

Abstract

BACKGROUND: Patients with malignant ascites (ma) usually experience poor quality of life, and treatment of this symptom remains a challenge. Oxidative stress, which can cause oxidative damage to dna, plays a pivotal role in carcinogenesis; however, the relationship between oxidative stress and dna damage to tumour-associated lymphocytes (tals) in ma is unclear.
METHODS: We measured the total antioxidant capacity (tac) of plasma and ma supernatant in 31 cancer patients with ma, and we used a comet assay to assess dna damage to both peripheral blood mononuclear cells (pbmcs) and tals. Measurements in age- and sex-matched healthy volunteers were used as controls.
RESULTS: The tac of plasma was remarkably lower in cancer patients (9.73 ± 1.96 U/mL) than in healthy control subjects (11.31 ± 1.50 U/mL, p < 0.001). The tac of ma supernatant (6.34 ± 1.57 U/mL) was significantly lower than that of plasma in cancer patients (7.42 ± 1.36 U/mL, p < 0.001). The comet percentage of pbmcs was higher in cancer patients (17.26% ± 6.04%) than in healthy control subjects (9.44% ± 4.47%, p < 0.01). In cancer patients, the comet percentage of tals (36.14% ± 17.85%) was significantly higher than that of pbmcs (17.26% ± 6.04%, p < 0.001). In cancer patients with ma, negative correlations were observed between plasma tac and dna damage to pbmcs (r = -0.505, p = 0.004) and between the tac of ma supernatant and the comet percentage of tals (r = -0.588, p = 0.001).
CONCLUSIONS: Results indicate the presence of significant oxidative damage to the dna of lymphocytes in peripheral blood and ascites from patients with ma, being especially higher in the cells from ascites. The lower tac of ma supernatant may be related to a higher degree of dna damage to tals. The present study suggests that an oxidant-antioxidant imbalance may be one of the mechanisms leading to the dna damage detected in peripheral blood and local tals in patients with ma, which may provide a novel approach to the treatment of ma.

Entities:  

Keywords:  Malignant ascites; dna damage; total antioxidant capacity; tumour-associated lymphocytes

Year:  2012        PMID: 22876163      PMCID: PMC3413254          DOI: 10.3747/co.19.1136

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  21 in total

Review 1.  Antioxidant measurements.

Authors:  Anikó Somogyi; Klára Rosta; Péter Pusztai; Zsolt Tulassay; Géza Nagy
Journal:  Physiol Meas       Date:  2007-03-07       Impact factor: 2.833

2.  World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  1997-03-19       Impact factor: 56.272

3.  A simple technique for quantitation of low levels of DNA damage in individual cells.

Authors:  N P Singh; M T McCoy; R R Tice; E L Schneider
Journal:  Exp Cell Res       Date:  1988-03       Impact factor: 3.905

4.  Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines.

Authors:  G Mantovani; A Macciò; M Pisano; R Versace; P Lai; S Esu; E Massa; M Ghiani; D Dessì; G B Melis; G S Del Giacco
Journal:  Int J Cancer       Date:  1997-05-29       Impact factor: 7.396

5.  Presence and specificity of tumor associated lymphocytes from ascites fluid in prostate cancer.

Authors:  Volkan Ozenci; Ashley M Miller; Andreas Palmborg; Lars Egevad; Georg A Jaremko; Karl Mikael Kälkner; Pavel Pisa
Journal:  Prostate       Date:  2005-09-15       Impact factor: 4.104

Review 6.  Total antioxidant capacity as a tool to assess redox status: critical view and experimental data.

Authors:  A Ghiselli; M Serafini; F Natella; C Scaccini
Journal:  Free Radic Biol Med       Date:  2000-12       Impact factor: 7.376

7.  Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.

Authors:  Tonya J Webb; Robert L Giuntoli; Ophelia Rogers; Jonathan Schneck; Mathias Oelke
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

8.  DNA damage of tumor-associated lymphocytes and total antioxidant capacity in cancerous patients.

Authors:  Xiaoju Liu; Jin Zhao; Rongliang Zheng
Journal:  Mutat Res       Date:  2003-08-05       Impact factor: 2.433

Review 9.  Treatment of malignant ascites.

Authors:  Michael Chung; Peter Kozuch
Journal:  Curr Treat Options Oncol       Date:  2008-09-06

10.  Total oxidant/antioxidant status in sera of patients with thyroid cancers.

Authors:  Dong Wang; Jia-Fu Feng; Ping Zeng; Yun-Hong Yang; Jun Luo; Yu-Wei Yang
Journal:  Endocr Relat Cancer       Date:  2011-12-01       Impact factor: 5.678

View more
  1 in total

1.  Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients.

Authors:  Weiwei Zhang; Kejun Liu; Bin Ye; Guolin Hu; Kelei Zhao; Yazhou Ren; Weijiang Liang
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.